Antiplatelet and Anticoagulant Therapy After Mechanical Thrombectomy for Ischemic Stroke
Start aspirin 160–325 mg within 24 hours after mechanical thrombectomy once intracranial hemorrhage has been excluded on repeat neuroimaging, then continue aspirin 75–100 mg daily indefinitely for secondary prevention.
This recommendation prioritizes mortality and morbidity reduction while minimizing hemorrhagic complications. The timing and choice of antiplatelet therapy depends critically on whether the patient received intravenous thrombolysis, the stroke severity, and whether intracranial stenting was performed during the procedure.
Immediate Post-Thrombectomy Management (First 24 Hours)
If IV Alteplase Was Given Before Thrombectomy
- Delay all antiplatelet agents until at least 24 hours after thrombolysis to minimize symptomatic intracranial hemorrhage risk. 1, 2
- Obtain repeat CT or MRI at 24 hours to confirm absence of hemorrhagic transformation before starting any antiplatelet therapy. 1, 2
- Once imaging confirms no hemorrhage, administer aspirin 160–325 mg as a loading dose, followed by 75–100 mg daily starting on day 2. 1, 3
If No IV Thrombolysis Was Given
- Aspirin can be started earlier (within 24 hours of thrombectomy) after confirming absence of intracranial hemorrhage on neuroimaging. 4
- A 2023 registry study of 190 patients demonstrated that early antiplatelet initiation (<24 hours post-thrombectomy) was independently associated with significantly increased odds of functional independence at discharge (OR 3.07) and 30 days (OR 5.78) without increased symptomatic intracranial hemorrhage. 4
- Administer aspirin 160–325 mg loading dose, then 75–100 mg daily maintenance. 1, 3
Special Circumstance: Intracranial Stenting During Thrombectomy
When Stenting Is Performed
- Dual antiplatelet therapy (aspirin + clopidogrel) must be initiated immediately when intracranial stenting is performed to prevent acute stent thrombosis, even if this occurs within 24 hours of IV thrombolysis. 5
- A 2020 case series of 6 patients who received antiplatelets within 24 hours of tPA (median 4.9 hours) for combined thrombectomy and stenting showed no symptomatic intracranial hemorrhage, suggesting acceptable safety in this select population. 5
Dosing Protocol for Stenting Cases
- Loading doses: Clopidogrel 300–600 mg + aspirin 160–325 mg administered immediately after stent placement. 3
- Maintenance: Clopidogrel 75 mg daily + aspirin 75–100 mg daily for 3 months, then transition to single antiplatelet therapy. 6
- A 2024 retrospective study of 147 patients demonstrated that 3-month DAPT after thrombectomy reduced recurrent stroke compared to 1-month DAPT (lower recurrence rate, P<0.05) without increasing mortality or symptomatic intracranial hemorrhage. 6
Duration and Choice of Antiplatelet Therapy
For Minor Stroke (NIHSS ≤3) Presenting Within 24 Hours
- Consider short-term dual antiplatelet therapy if the patient meets criteria for minor stroke or high-risk TIA. 3
- Loading: Clopidogrel 300 mg + aspirin 160–325 mg within 24 hours of symptom onset. 3
- Maintenance: Clopidogrel 75 mg + aspirin 75–100 mg daily for exactly 21 days, then switch to single antiplatelet therapy. 3
- This regimen reduces 90-day recurrent stroke by approximately 32% (pooled RR 0.68,95% CI 0.55–0.83) with acceptable bleeding risk (0.9% vs 0.4% with aspirin alone). 3
For Moderate-to-Severe Stroke (NIHSS >3)
- Single antiplatelet therapy with aspirin is recommended rather than dual therapy. 3
- Loading: Aspirin 160–325 mg within 24–48 hours after hemorrhage exclusion. 1, 3
- Maintenance: Aspirin 75–100 mg daily indefinitely. 1, 3
Long-Term Secondary Prevention (Beyond Acute Phase)
First-Line Options
- Aspirin 75–100 mg daily is the first-line choice for most patients. 1
- Clopidogrel 75 mg daily is an equally effective alternative, particularly preferred for patients with diabetes, aspirin intolerance, or peripheral arterial disease. 1, 3
- Aspirin 25 mg + extended-release dipyridamole 200 mg twice daily is another acceptable regimen. 1, 3
Critical Contraindication
- Do NOT continue dual antiplatelet therapy beyond 21–30 days (or 3 months if stenting was performed) unless a separate cardiac indication exists, as prolonged DAPT markedly increases major bleeding risk (HR 2.22–2.32) without additional stroke prevention benefit. 3
Anticoagulation Considerations
When to Use Anticoagulation Instead of Antiplatelets
- If atrial fibrillation or another cardioembolic source is identified, transition to oral anticoagulation rather than antiplatelet therapy. 1
- Direct oral anticoagulants (DOACs) are preferred over warfarin for nonvalvular atrial fibrillation. 1
- Timing: Anticoagulation initiation after acute stroke should follow the "1-3-6-12 day rule" based on infarct size, but this is beyond the scope of immediate post-thrombectomy management. 1
Anticoagulation Is NOT Recommended
- For noncardioembolic stroke, antiplatelet therapy is superior to anticoagulation for secondary prevention. 1, 3
- Routine anticoagulation after thrombectomy without a cardioembolic source increases bleeding risk without benefit. 1
Safety Monitoring and Common Pitfalls
Hemorrhagic Risk
- Symptomatic intracranial hemorrhage occurs in 2.4–6.4% of patients receiving IV thrombolysis. 7
- A 2023 study of 646 thrombectomy patients (13% on anticoagulation, 30.3% on antiplatelets pre-stroke) showed no significant difference in symptomatic intracranial hemorrhage rates between groups (7.3% overall), confirming the safety of thrombectomy in patients on prior antithrombotic therapy. 8
Recurrent Stroke Risk
- A 2026 meta-analysis of 15 RCTs (n=4,898) comparing thrombectomy versus medical management found no difference in early recurrent stroke rates (5.5% vs 4.5%; RR 1.2,95% CI 0.9–1.6), indicating that thrombectomy itself does not increase recurrent stroke risk. 9
Critical Pitfalls to Avoid
- Do NOT delay aspirin beyond 48 hours when eligibility criteria are met; maximal benefit occurs within the first 24–48 hours. 1, 3
- Do NOT use aspirin as a substitute for thrombectomy in eligible patients; this delays definitive treatment and worsens outcomes. 3
- Do NOT use glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) in acute ischemic stroke; they are potentially harmful. 3, 2
- Do NOT use ticagrelor instead of clopidogrel for acute stroke; it carries higher bleeding risk without proven benefit. 3
Special Populations
Severe Renal Impairment (CrCl <30 mL/min)
- Use aspirin monotherapy only; clopidogrel is contraindicated due to metabolite accumulation and heightened bleeding risk. 3
- Dosing: Aspirin 160–325 mg loading, then 75–100 mg daily maintenance. 3